Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure
A Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of BMS-986259 in Stabilized Patients Hospitalized for Acute Decompensated Heart Failure
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Cordoba, Argentina, 5006
- Local Institution - 0025
-
-
Buenos Aires
-
Ciudad de Buenos Aires, Buenos Aires, Argentina, 1180
- Local Institution - 0009
-
-
Cordoba
-
Alberdi, Cordoba, Argentina, 5000
- Local Institution - 0007
-
Córdoba, Cordoba, Argentina, X5000EPU
- Local Institution - 0010
-
-
Distrito Federal
-
Ciudad Autónoma de Buenos Aires, Distrito Federal, Argentina, C1093AAS
- Local Institution
-
-
Provincia DE Cordoba
-
Cordoba, Provincia DE Cordoba, Argentina, 5000
- Local Institution - 0028
-
-
-
-
-
Praha 2, Czechia, 12808
- Local Institution - 0020
-
Slany, Czechia, 274 01
- Nemocnice Slany-Interna - kardiologicka ambulance
-
-
-
-
-
Athens, Greece, 11527
- Local Institution - 0011
-
Athens, Greece, 142 33
- Local Institution - 0022
-
-
-
-
-
Jerusalem, Israel, 912001
- Local Institution
-
Petah Tikva, Israel, 4941492
- Local Institution
-
-
Tell Abīb
-
Tel Aviv, Tell Abīb, Israel, 6423906
- Local Institution - 0014
-
-
-
-
-
Bialystok, Poland, 15 276
- Local Institution - 0034
-
Wrocaw, Poland, 50-556
- Local Institution - 0030
-
Wroclaw, Poland, 54-049
- Local Institution - 0027
-
-
-
-
-
Edinburgh, United Kingdom, EH16 4SA
- Local Institution
-
Swindon, United Kingdom, SN3 6BB
- Local Institution
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- Participants currently hospitalized for acute decompensated heart failure (ADHF)
- Participants must be hemodynamically stable, as assessed by the investigator
- Men must agree to follow specific methods of contraception, if applicable, while participating in the trial
- Women participants must have documented proof that they are not of childbearing potential
Exclusion Criteria:
- Acute cardiovascular condition other than heart failure (HF) decompensation
- Cardiogenic shock at presentation to emergency room (ER) or at any time before randomization
- Recipient of ventricular assist devices or use of any cardiac extracorporeal devices, within 12 weeks of study randomization
- Participants with contraindications to vasodilator therapy such as restrictive or obstructive cardiomyopathy, severe mitral or aortic stenosis
Other protocol-defined inclusion/exclusion criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Specified dose on specified days
|
|
Experimental: BMS-986259
|
Specified dose on specified days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Experiencing Clinically Relevant Hypotension
Time Frame: From first dose to 30 days following first dose
|
Clinically Relevant Hypotension is defined as occurrence of any of the following:
|
From first dose to 30 days following first dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum Observed Serum Concentration (Cmax)
Time Frame: Day 1 and Day 5 of study treatment
|
Day 1 and Day 5 of study treatment
|
|
Time of Maximum Observed Serum Concentration (Tmax)
Time Frame: Day 1 and Day 5 of study treatment
|
Day 1 and Day 5 of study treatment
|
|
Area Under the Concentration-Time Curve Within a Dosing Interval (AUC(TAU))
Time Frame: Day 1 and Day 5 of study treatment
|
Day 1 and Day 5 of study treatment
|
|
Trough Concentration (Ctrough)
Time Frame: Day 2 through Day 14 of study treatment (with the exception of Day 11, for which data is not available)
|
Day 2 through Day 14 of study treatment (with the exception of Day 11, for which data is not available)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CV019-010
- 2019-004186-40 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.